Wiley
SCOPUS (SonsInc.)SCIE-ISI
2523-3548
2523-3548
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Các bài báo tiêu biểu
Breast cancer is the most commonly diagnosed cancer and leading cause of cancer death among women worldwide but has patterns and trends which vary in different countries. This study aimed to evaluate the global patterns of breast cancer incidence and mortality and analyze its temporal trends for breast cancer prevention and control.
Breast cancer incidence and mortality data in 2020 were obtained from the GLOBOCAN online database. Continued data from the Cancer Incidence in Five Continents Time Trends, the International Agency for Research on cancer mortality and China National Central Cancer Registry were used to analyze the time trends from 2000 to 2015 through Joinpoint regression, and annual average percent changes of breast cancer incidence and mortality were calculated. Association between Human Development Index and breast cancer incidence and mortality were estimated by linear regression.
There were approximately 2.3 million new breast cancer cases and 685,000 breast cancer deaths worldwide in 2020. Its incidence and mortality varied among countries, with the age‐standardized incidence ranging from the highest of 112.3 per 100,000 population in Belgium to the lowest of 35.8 per 100,000 population in Iran, and the age‐standardized mortality from the highest of 41.0 per 100,000 population in Fiji to the lowest of 6.4 per 100,000 population in South Korea. The peak age of breast cancer in some Asian and African countries were over 10 years earlier than in European or American countries. As for the trends of breast cancer, the age‐standardized incidence rates significantly increased in China and South Korea but decreased in the United States of America (USA) during 2000‐2012. Meanwhile, the age‐standardized mortality rates significantly increased in China and South Korea but decreased in the United Kingdom, the USA, and Australia during 2000 and 2015.
The global burden of breast cancer is rising fast and varies greatly among countries. The incidence and mortality rates of breast cancer increased rapidly in China and South Korea but decreased in the USA. Increased health awareness, effective prevention strategies, and improved access to medical treatment are extremely important to curb the snowballing breast cancer burden, especially in the most affected countries.
Cancer is still a major health problem in China although numerous efforts have been made for its prevention and control. Findings from this study showed that lung cancer remains the most common type of cancer diagnosed, and was attributed to nearly 30% of all cancer‐related deaths. The incidence of the five most common cancers, in China, in 2015, including cancers of the lungs, stomach, colorectum, liver and breast, accounted for almost 60% of all cancers diagnosed. The high cancer burden in China highlights the need for further improvement in health education, professional training and the building up an anti‐cancer network for introducing and implementing sustainable actions for cancer control.
Mucinous colorectal adenocarcinoma is a distinct subtype of colorectal cancer (CRC) characterized by the presence of abundant extracellular mucin which accounts for at least 50% of the tumor volume. Mucinous colorectal adenocarcinoma is found in 10%–20% of CRC patients and occurs more commonly in female and younger patients. Moreover, mucinous colorectal adenocarcinoma is more frequently located in the proximal colon and diagnosed at an advanced stage. Based on its molecular context, mucinous colorectal adenocarcinoma is associated with the overexpression of mucin 2 (MUC2) and mucin 5AC (MUC5AC) proteins. At the same time, it shows higher mutation rates in the fundamental genes of the RAS/MAPK and PI3K/Akt/mTOR pathways. Mucinous colorectal adenocarcinoma also shows higher rates of microsatellite instability (MSI) than non‐mucinous colorectal adenocarcinoma which might correlate it with Lynch syndrome and the CpG island methylator phenotype. The prognosis of mucinous colorectal adenocarcinoma as to non‐mucinous colorectal adenocarcinoma is debatable. Further, the impaired responses of mucinous colorectal adenocarcinoma to palliative or adjuvant chemotherapy warrant more studies to be performed for a specialized treatment for these patients. In this review, we discuss the molecular background and histopathology of mucinous colorectal adenocarcinoma, and provide an update on its prognosis and therapeutics from recent literatures.
Lung cancer is the leading cause of cancer mortality worldwide. Dendritic cells (DCs) are the key factors providing protective immunity against lung tumors and clinical trials have proven that DC function is reduced in lung cancer patients. It is evident that the immunoregulatory network may play a key role in the failure of the immune response to terminate tumors. Lung tumors likely employ numerous strategies to suppress DC‐based anti‐tumor immunity. Here, we summarize the recent advances in our understanding on lung tumor‐induced immunosuppression in DCs, which affects the initiation and development of T‐cell responses. We also describe which existing measures to restore DC function may be useful for clinical treatment of lung tumors. Furthering our knowledge of how lung cancer cells alter DC function to generate a tumor‐supportive environment will be essential in order to guide the design of new immunotherapy strategies for clinical use.
Độc tính tim mạch liên quan đến 5‐fluorouracil (5‐FU) và capecitabine, từ các bất thường điện tâm đồ không có triệu chứng cho đến nhồi máu cơ tim nghiêm trọng, đã được báo cáo trong một số nghiên cứu. Tuy nhiên, tình trạng độc tính tim mạch này ở bệnh nhân Trung Quốc có bệnh ác tính vẫn chưa được điều tra đến nay. Trong nghiên cứu hiện tại, chúng tôi nhằm đánh giá một cách triển vọng tỷ lệ xảy ra và các biểu hiện lâm sàng của độc tính tim mạch liên quan đến 5‐FU và capecitabine ở bệnh nhân ung thư được tuyển chọn từ nhiều trung tâm tại Trung Quốc.
Trong số 527 bệnh nhân hoàn thành nghiên cứu, 196 người được điều trị hóa chất dựa trên 5‐FU và 331 người được điều trị hóa chất dựa trên capecitabine với tư cách là liệu pháp đầu tay hoặc bổ trợ. Các biến cố bất lợi đã được báo cáo trong suốt quá trình điều trị và lên đến 28 ngày theo dõi. Các chỉ số kết quả bao gồm điện tâm đồ (ECG), enzyme cơ tim, troponin tim, peptide natri lợi niệu và siêu âm tim. Phân tích đơn biến và hồi quy logistic đã được tiến hành để phân tích theo nhóm và xác định các biến số độc lập có ý nghĩa liên quan đến độc tính tim mạch của cả hai loại thuốc này.
Tổng cộng, 161 trên 527 bệnh nhân (30.6%) trải qua độc tính tim mạch. Tỷ lệ xảy ra của độc tính tim mạch là 33.8% (112/331) trong nhóm capecitabine, cao hơn đáng kể so với tỷ lệ 25% (49/196) trong nhóm 5‐FU (
Độc tính tim mạch do fluoropyrimidine gây ra trong dân số Trung Quốc có thể bị đánh giá thấp trong thực hành lâm sàng. Việc theo dõi chặt chẽ bệnh nhân được khuyến nghị, đặc biệt là đối với những bệnh nhân có nguy cơ cao về độc tính tim mạch. Các yếu tố nguy cơ có thể bao gồm thời gian điều trị, hóa trị liệu dựa trên capecitabine, các bệnh tim mạch hiện có và tăng huyết áp.
A growing body of evidence supports the use of laparoscopic pancreaticoduodenectomy (LPD) as an efficient and feasible surgical technique. However, few studies have investigated its applicability in pancreatic ductal adenocarcinoma (PDAC), and the long‐term efficacy of LPD on PDAC remains unclear. This study aimed to compare the short‐ and long‐term outcomes between LPD and open pancreaticoduodenectomy (OPD) for PDAC.
The data of patients who had OPD or LPD for PDAC between January 2013 and September 2017 were retrieved. Their postoperative outcomes and survival were compared after propensity score matching.
A total of 309 patients were included. After a 2:1 matching, 93 cases in the OPD group and 55 in the LPD group were identified. Delayed gastric emptying (DGE), particularly grade B/C DGE, occurred less frequently in the LPD group than in the OPD group (1.8% vs. 36.6%,
LPD was found to be technically feasible with efficacy similar to OPD for patients with PDAC.
Cancer cells reprogram metabolism for proliferation. Phosphoglycerate kinase 1 (PGK1), as a glycolytic enzyme and newly identified protein kinase, coordinates glycolysis and mitochondrial metabolism. However, the clinical significance of PGK1 expression and function in cancer progression is unclear. Here, we investigated the relationship between the progression and prognosis of multiple cancer types and PGK1 expression and its function in the mitochondrial metabolism regulation.
We performed pan‐cancer analyses of
The
The elevated expression, promoter hypomethylation, and phosphorylation of PGK1 and PDHK1 were related with disease progression and short OS in diverse types of cancer. PGK1 and PDHK1 phosphorylation may be potential prognostic biomarkers.
Overexpression of ATP‐binding cassette (ABC) transporter is a major contributor to multidrug resistance (MDR), in which cancer cells acquire resistance to a wide spectrum of chemotherapeutic drugs. In this work, we evaluated the sensitizing effect of sitravatinib, a broad‐spectrum tyrosine kinase inhibitor (TKI), on ATP‐binding cassette subfamily B member 1 (ABCB1)‐ and ATP‐binding cassette subfamily C member 10 (ABCC10)‐mediated MDR.
MTT assay was conducted to examine cytotoxicity and evaluate the sensitizing effect of sitravatinib at non‐toxic concentrations. Tritium‐labeled paclitaxel transportation, Western blotting, immunofluorescence analysis, and ATPase assay were carried out to elucidate the mechanism of sitravatinib‐induced chemosensitization. The
Sitravatinib considerably reversed MDR mediated by ABCB1 and partially antagonized ABCC10‐mediated MDR. Our
The findings in this study suggest that the combination of sitrvatinib and substrate antineoplastic drugs of ABCB1 could attenuate the MDR mediated by the overexpression of ABCB1.